DK3555097T3 - Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser - Google Patents
Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser Download PDFInfo
- Publication number
- DK3555097T3 DK3555097T3 DK17854175.1T DK17854175T DK3555097T3 DK 3555097 T3 DK3555097 T3 DK 3555097T3 DK 17854175 T DK17854175 T DK 17854175T DK 3555097 T3 DK3555097 T3 DK 3555097T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrrolo
- imidazo
- inhibitors
- pyridine compounds
- janus kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662435609P | 2016-12-16 | 2016-12-16 | |
US201762592680P | 2017-11-30 | 2017-11-30 | |
US201762596607P | 2017-12-08 | 2017-12-08 | |
PCT/US2017/066744 WO2018112379A1 (en) | 2016-12-16 | 2017-12-15 | Small molecule inhibitors of the jak family of kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3555097T3 true DK3555097T3 (da) | 2022-07-25 |
Family
ID=61692222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17854175.1T DK3555097T3 (da) | 2016-12-16 | 2017-12-15 | Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser |
Country Status (34)
Country | Link |
---|---|
US (5) | US10294226B2 (da) |
EP (2) | EP4086256A1 (da) |
JP (2) | JP7291077B2 (da) |
KR (1) | KR102352462B1 (da) |
CN (1) | CN110088105B (da) |
AU (3) | AU2017377069B2 (da) |
BR (1) | BR112019011968A2 (da) |
CA (1) | CA3046965A1 (da) |
CL (1) | CL2019001626A1 (da) |
CO (1) | CO2019006200A2 (da) |
CR (1) | CR20190282A (da) |
DK (1) | DK3555097T3 (da) |
EC (1) | ECSP19042688A (da) |
ES (1) | ES2922379T3 (da) |
HR (1) | HRP20220885T1 (da) |
HU (1) | HUE059274T2 (da) |
IL (1) | IL267275B (da) |
JO (1) | JOP20190143B1 (da) |
LT (1) | LT3555097T (da) |
MD (1) | MD3555097T2 (da) |
MX (2) | MX2019007073A (da) |
MY (1) | MY196260A (da) |
NI (1) | NI201900060A (da) |
PE (1) | PE20191105A1 (da) |
PH (1) | PH12019501254A1 (da) |
PL (1) | PL3555097T3 (da) |
PT (1) | PT3555097T (da) |
RS (1) | RS63500B1 (da) |
SA (1) | SA519402216B1 (da) |
SI (1) | SI3555097T1 (da) |
TW (1) | TWI777997B (da) |
UA (1) | UA125042C2 (da) |
WO (1) | WO2018112379A1 (da) |
ZA (1) | ZA201904615B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物 |
JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Jakファミリーのキナーゼの低分子阻害物質 |
JOP20190144A1 (ar) * | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
JP2021527650A (ja) | 2018-06-15 | 2021-10-14 | リアタ ファーマシューティカルズ インコーポレイテッド | IL−17およびRORγの阻害用のピラゾール化合物およびイミダゾール化合物 |
TW202016110A (zh) * | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
KR20220016955A (ko) * | 2019-06-06 | 2022-02-10 | 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
CN110483514B (zh) * | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | 一种氰基取代的环肼衍生物及其应用 |
AU2021222686B2 (en) * | 2020-02-21 | 2023-06-29 | Zhuhai United Laboratories Co., Ltd. | Crystalline form of JAK inhibitor and application thereof |
CN114149428B (zh) * | 2020-09-08 | 2023-06-13 | 中国药科大学 | 吡啶并环类化合物及其制备方法、中间体、组合物和应用 |
KR20230156752A (ko) | 2021-03-11 | 2023-11-14 | 얀센 파마슈티카 엔브이 | Jak 매개 장애의 치료에 사용하기 위한 로르푸시티닙 |
CN113292561A (zh) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | 一种二吡咯并吡啶结构的化合物、制备方法和医药用途 |
CN114432317A (zh) * | 2021-05-31 | 2022-05-06 | 广州嘉越医药科技有限公司 | 吡咯并嘧啶类化合物的用途 |
CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
CA2615291A1 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
CN102118968A (zh) | 2008-06-10 | 2011-07-06 | 雅培制药有限公司 | 新的三环化合物 |
JP2011066747A (ja) * | 2009-09-18 | 2011-03-31 | Panasonic Corp | 弾性波フィルタ |
WO2011068899A1 (en) | 2009-12-01 | 2011-06-09 | Abbott Laboratories | Novel tricyclic compounds |
KR20170118230A (ko) | 2009-12-01 | 2017-10-24 | 애브비 인코포레이티드 | 신규한 트리사이클릭 화합물 |
CN102712640A (zh) * | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
CA2789186A1 (en) | 2010-02-10 | 2011-08-18 | Genon Biotechnologies Oy | Dual activity kinase domains and uses thereof |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
CA2983453A1 (en) | 2015-05-28 | 2016-12-01 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
EP3371332A4 (en) | 2015-11-04 | 2019-04-03 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES |
SG11201903182XA (en) | 2016-10-24 | 2019-05-30 | Astrazeneca Ab | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
RS61108B1 (sr) | 2016-12-16 | 2020-12-31 | Lilly Co Eli | Jedinjenja 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ona kao inhibitori idh1 i idh2 mutanta |
EA037318B1 (ru) | 2016-12-16 | 2021-03-11 | Пфайзер Инк. | Агонисты рецептора glp-1 и их применение |
PE20191322A1 (es) | 2016-12-16 | 2019-09-24 | Basf Se | Compuestos plaguicidas |
JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
US20190281874A1 (en) | 2016-12-16 | 2019-09-19 | Nestec S.A. | Oligosaccharides for flavour generation |
JP7291077B2 (ja) | 2016-12-16 | 2023-06-14 | ヤンセン ファーマシューティカ エヌ.ベー. | Jakファミリーのキナーゼの低分子阻害物質 |
LT3494116T (lt) | 2017-01-30 | 2020-01-10 | Astrazeneca Ab | Estrogeno receptorių moduliatoriai |
SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Jak激酶家族之小分子抑制劑 |
WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
-
2017
- 2017-12-15 JP JP2019531668A patent/JP7291077B2/ja active Active
- 2017-12-15 ES ES17854175T patent/ES2922379T3/es active Active
- 2017-12-15 MX MX2019007073A patent/MX2019007073A/es unknown
- 2017-12-15 HU HUE17854175A patent/HUE059274T2/hu unknown
- 2017-12-15 EP EP22178880.5A patent/EP4086256A1/en active Pending
- 2017-12-15 PL PL17854175.1T patent/PL3555097T3/pl unknown
- 2017-12-15 CA CA3046965A patent/CA3046965A1/en active Pending
- 2017-12-15 LT LTEPPCT/US2017/066744T patent/LT3555097T/lt unknown
- 2017-12-15 EP EP17854175.1A patent/EP3555097B1/en active Active
- 2017-12-15 HR HRP20220885TT patent/HRP20220885T1/hr unknown
- 2017-12-15 JO JOP/2019/0143A patent/JOP20190143B1/ar active
- 2017-12-15 PT PT178541751T patent/PT3555097T/pt unknown
- 2017-12-15 MX MX2022004474A patent/MX2022004474A/es unknown
- 2017-12-15 TW TW106144095A patent/TWI777997B/zh active
- 2017-12-15 RS RS20220753A patent/RS63500B1/sr unknown
- 2017-12-15 SI SI201731186T patent/SI3555097T1/sl unknown
- 2017-12-15 UA UAA201908086A patent/UA125042C2/uk unknown
- 2017-12-15 BR BR112019011968-0A patent/BR112019011968A2/pt active Search and Examination
- 2017-12-15 KR KR1020197020121A patent/KR102352462B1/ko active IP Right Grant
- 2017-12-15 MY MYPI2019003389A patent/MY196260A/en unknown
- 2017-12-15 PE PE2019001252A patent/PE20191105A1/es unknown
- 2017-12-15 AU AU2017377069A patent/AU2017377069B2/en active Active
- 2017-12-15 MD MDE20191212T patent/MD3555097T2/ro unknown
- 2017-12-15 CR CR20190282A patent/CR20190282A/es unknown
- 2017-12-15 CN CN201780077753.4A patent/CN110088105B/zh active Active
- 2017-12-15 WO PCT/US2017/066744 patent/WO2018112379A1/en active Application Filing
- 2017-12-15 DK DK17854175.1T patent/DK3555097T3/da active
- 2017-12-15 US US15/843,642 patent/US10294226B2/en active Active
-
2019
- 2019-01-09 US US16/243,874 patent/US10364246B2/en active Active
- 2019-02-12 US US16/274,142 patent/US11059823B2/en active Active
- 2019-02-13 US US16/275,045 patent/US10487083B2/en active Active
- 2019-06-06 PH PH12019501254A patent/PH12019501254A1/en unknown
- 2019-06-12 IL IL267275A patent/IL267275B/en unknown
- 2019-06-12 CL CL2019001626A patent/CL2019001626A1/es unknown
- 2019-06-13 SA SA519402216A patent/SA519402216B1/ar unknown
- 2019-06-14 NI NI201900060A patent/NI201900060A/es unknown
- 2019-06-14 EC ECSENADI201942688A patent/ECSP19042688A/es unknown
- 2019-06-14 CO CONC2019/0006200A patent/CO2019006200A2/es unknown
- 2019-07-15 ZA ZA2019/04615A patent/ZA201904615B/en unknown
-
2020
- 2020-10-21 AU AU2020257068A patent/AU2020257068A1/en not_active Abandoned
-
2021
- 2021-06-23 US US17/355,472 patent/US20210340143A1/en active Pending
-
2022
- 2022-06-17 AU AU2022204240A patent/AU2022204240B2/en active Active
-
2023
- 2023-02-13 JP JP2023019626A patent/JP7493068B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3555097T3 (da) | Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser | |
DK3523301T3 (da) | Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer | |
DK3523302T3 (da) | Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer | |
HUS2200003I1 (hu) | Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai | |
DK3478682T3 (da) | [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser | |
HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1,5-a]吡啶化合物 | |
DK3808749T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme | |
DK3134413T3 (da) | Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer | |
DK3712152T3 (da) | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer | |
DK3371185T3 (da) | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer | |
DK3840832T3 (da) | Imidazo[1,2-b]pyridaziner som trk-inhibitorer | |
MA46690A (fr) | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 | |
DK3679042T3 (da) | Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer |